128 related articles for article (PubMed ID: 28978265)
21. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
22. Tracking evolution of BRCA1-associated breast cancer.
Jonkers J
Cancer Discov; 2012 Jun; 2(6):486-8. PubMed ID: 22684454
[TBL] [Abstract][Full Text] [Related]
23. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
24. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
25. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor.
Muthuvel SK; Elumalai E; K G; K H
J Recept Signal Transduct Res; 2018; 38(5-6):475-483. PubMed ID: 31038021
[TBL] [Abstract][Full Text] [Related]
26. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
27. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
28. Computational design of Tryprostatin-A derivatives as novel αβ-tubulin inhibitors.
Fani N; Bordbar AK; Ghayeb Y; Sepehri S
J Biomol Struct Dyn; 2015; 33(3):471-86. PubMed ID: 24606044
[TBL] [Abstract][Full Text] [Related]
29. Integrating docking and molecular dynamics approaches for a series of proline-based 2,5-diketopiperazines as novel αβ-tubulin inhibitors.
Fani N; Bordbar AK; Ghayeb Y; Sepehri S
J Biomol Struct Dyn; 2015; 33(10):2285-95. PubMed ID: 25616934
[TBL] [Abstract][Full Text] [Related]
30. Ligand and structure based virtual screening of chemical databases to explore potent small molecule inhibitors against breast invasive carcinoma using recent computational technologies.
Agarwal S; Dixit A; Kashaw SK
J Mol Graph Model; 2020 Jul; 98():107591. PubMed ID: 32234678
[TBL] [Abstract][Full Text] [Related]
31. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
Garg S; Singh J; Verma SR
J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting of
Na B; Yu X; Withers T; Gilleran J; Yao M; Foo TK; Chen C; Moore D; Lin Y; Kimball SD; Xia B; Ganesan S; Carpizo DR
NPJ Breast Cancer; 2019; 5():14. PubMed ID: 30993195
[TBL] [Abstract][Full Text] [Related]
33. TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro.
Rasti M; Azimi T
Avicenna J Med Biotechnol; 2015; 7(2):76-9. PubMed ID: 26140185
[TBL] [Abstract][Full Text] [Related]
34. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
[TBL] [Abstract][Full Text] [Related]
35. Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families.
Balz V; Prisack HB; Bier H; Bojar H
Cancer Genet Cytogenet; 2002 Oct; 138(2):120-7. PubMed ID: 12505256
[TBL] [Abstract][Full Text] [Related]
36. In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Thillainayagam M; Malathi K; Ramaiah S
J Biomol Struct Dyn; 2018 Nov; 36(15):3993-4009. PubMed ID: 29132266
[TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
[TBL] [Abstract][Full Text] [Related]
38. LC-MS/MS-based targeted proteomics quantitatively detects the interaction between p53 and MDM2 in breast cancer.
Zhang W; Zhong T; Chen Y
J Proteomics; 2017 Jan; 152():172-180. PubMed ID: 27826076
[TBL] [Abstract][Full Text] [Related]
39. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
[TBL] [Abstract][Full Text] [Related]
40. p53, BRCA1 and breast Cancer chemoresistance.
Scata KA; El-Deiry WS
Adv Exp Med Biol; 2007; 608():70-86. PubMed ID: 17993233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
